London, UK, 23 November 2006, BioProgress plc (‘BioProgress’ or the ‘Company’) (AIM: BPRG; NASDAQ: BPRG), the speciality pharma and healthcare company, is pleased to announce an update on its agreement with licensing partner FMC Corporation (“FMC”) for its NRobeTM technology, an oral drug delivery technology.
